Effect of obstructive sleep apnea on cerebrovascular compliance and cerebral small vessel disease.

Reduced cerebrovascular compliance is the major mechanism of cerebral small vessel disease (SVD). Obstructive sleep apnea (OSA) also promotes SVD development, but the underlying mechanism was not elucidated. We investigated the association among OSA, cerebrovascular compliance, and SVD parameters. This study retrospectively included individuals ≥ 50 years of age, underwent overnight polysomnographic (PSG) for the evaluation of OSA, and performed MRI and transcranial Doppler (TCD) within 12 months of interval without a neurological event between the evaluations. TCD parameters for the cerebrovascular compliance included middle cerebral artery pulsatility index (MCA PI) and mean MCA resistance index ratio (MRIR). SVD parameters included white matter hyperintensity (WMH) volume, number of lacunes, enlarged perivascular space (ePVS) score, and the presence of microbleeds or lacunes. Ninety-seven individuals (60.8% male, mean age 70.0±10.5 years) were included. MRIR was associated with higher respiratory distress index (B = 0.003; 95% confidence interval [CI] 0.001-0.005; P = 0.021), while MCA PI was not associated with any of the PSG markers for OSA severity. Apnea-hypopnea index was associated with the log-transformed total WMH volume (B = 0.008; 95% confidence interval [CI] 0.001-0.016; P = 0.020), subcortical WMH volume (B = 0.015; 95% CI 0.007-0.022; P<0.001), total ePVS score (B = 0.024; 95% CI 0.003-0.045; P = 0.026), and centrum semiovale ePVS score (B = 0.026; 95% CI 0.004-0.048; P = 0.019), and oxygen-desaturation index with periventricular WMH volume, independently from age, MCA PI, and MRIR. This study concluded that OSA is associated with reduced cerebrovascular compliance and also with SVD independently from cerebrovascular compliance. Underlying pathomechanistic link might be region specific.

Introduction

Cerebral small vessel disease (SVD) is a very prevalent age-related phenomenon of the brain [1, 2]. There is no approved treatment for SVD, although a recent randomized study has shown that remote ischemic conditioning reduces the recurrence of ischemic stroke and is an effective therapy for patients with SVD [3]. Reduced compliance in the cerebral arterioles resulting from chronic dysregulated vascular remodeling has been regarded the fundamental pathomechanism of SVD progression, which provokes the blood-brain-barrier (BBB) damage, intermittent hypoperfusion, and impaired clearance of the cerebral waste and ultimately leads to the chronic inflammation and subclinical ischemia in the brain parenchyma [2, 4–7].

Obstructive sleep apnea (OSA) is a very prevalent sleep related breathing disorder in elderly population. The reported incidence of OSA is from 5.6% to 60% in people over 65 while SVD presents an increased one from 6% at age 60 to 28% at age 80 [8]. Aging is associated with an increased risk and severity of OSA, and OSA has also been shown to be related to olfactory disorders, the origin of which could be attributed to disorders of the central nervous system [9].

OSA and SVD share common risk factors such as increasing age, hypertension, diabetes, and obesity, and OSA is associated with the progression of SVD [10-12]. OSA is implicated in the endothelial dysfunction and decreased vascular compliance [7, 9, 13, 14]. A recent study suggested that endothelial dysfunction in OSA may be related to the consequent generation of reactive oxygen species and pro-inflammatory molecules, resulting in microvascular damage in OSA patients [15]. However, the effect of OSA on SVD progression is independent from those cerebrovascular risk factors and its underlying mechanisms might be distinct from the dysregulated vascular remodeling [16, 17]. The candidate pathophysiologic link between OSA and SVD includes abrupt increment in the intrathoracic pressure that interferes with the adequate venous return and cardiac output, frequent arousal, intermittent brain hypoxia, and provocation of arrhythmia [13, 18–20]. Frequent arousal and intermittent hypoxia can recurrently activate the sympathetic nervous system, provoke oxidative stress, and induce parenchymal inflammation [13, 18, 21–23]. Also, altered intrathoracic pressure and frequent arousal might impair the activation of cerebral waste clearance system during sleep [13, 19, 20, 24–26]. Although highly interrelated, discrimination of the major mechanism underlying the progression of SVD in patients with OSA might be important to predict how the adequate treatment of OSA could also modify the progression of SVD [27, 28].

Transcranial Doppler sonography (TCD) is a widely used noninvasive method to measure the blood flow in the brain [29]. Some parameters of TCD are useful indicators for the cerebrovascular compliance [30]. Pulsatility index (PI) evaluates the stiffness of the vessel and also the resistance of the distal arterial bed [31, 32]. Recently, it is reported that a reduction of resistance index (RI) along the middle cerebral artery (MCA RI ratio, MRIR) might be an indirect marker for the compliance of the cerebral small vessels [30].

In this study, we aimed to determine the pathomechanism linking OSA, altered cerebrovascular compliance, and SVD development. In this regard, we investigated whether the polysomnographic (PSG) parameters for the OSA severity was associated with the TCD parameters for the cerebrovascular compliance. Then, we evaluated the associations of the OSA severity factors and the vascular compliance markers with the parameters of cerebral SVD, such as white matter hyperintensity (WMH) volume, enlarged perivascular space (ePVS) score, and the presence of cerebral microbleeds (CMB) or lacunes.

Materials and methods

Study subjects and clinical data

The design of this study was approved by the institutional review board of Seoul National University Boramae Hospital. Informed consent was waived by the IRB, as this study did not intervene with the evaluation or treatment process of the patients, and the patients were anonymized during the study process. This retrospective cohort study initially included all consecutive individuals who were ≥ 50 years of age, visited Seoul National University Boramae Hospital between March 2008 and August 2019, underwent overnight PSG evaluation to evaluate for the presumptive diagnosis of OSA, and performed MRI and TCD within 12 months of interval. Among the initially included 175 individuals, the final study population was defined according to the following criteria: (1) no significant (≥ 50%) stenosis in the internal carotid arteries (ICAs) or the MCAs at the initial magnetic resonance angiography (MRA) or TCD; (2) no history of stroke other than an old lacunar stroke (> 90 days); (3) able to carry out daily activities independently without a neurological deficit; and (4) adequate temporal window for a TCD evaluation. According to the criteria, 15 patients with significant stenosis in the ICAs or the MCAs, 45 with a stroke history other than an old lacunar stroke, 11 with fixed neurological deficit or incapable of independent daily living, and 7 with inadequate temporal window were sequentially excluded and the remaining 97 individuals were included for the study analysis. Clinical profiles including demographics, history of lacunar infarction, and presence of hypertension, diabetes mellitus, hyperlipidemia, congestive heart failure, and atrial fibrillation were obtained from the patients’ medical record. The design of this study was approved by the institutional review board of Seoul National University Boramae Hospital.

Transcranial Doppler evaluation

Intracranial arteries were sonographically evaluated using a 2-MHz pulsed-wave and range-gated TCD probe (Digital PMD 100 or ST3 Digital PMD 150; Spencer Technologies; Redmond, WA, USA) with a transmission power level of 100 mW/cm2, pulse repetition frequency of 8000 Hz, filter frequency of 200 Hz, gain of 4 decibels, and range of 200 decibels. The TCD evaluation protocol was standardized for every patient and was conducted by two skilled sonographers with 17 and 10 years of experience, respectively. The flow in the MCA, the anterior cerebral artery, and the internal carotid artery (ICA) was evaluated to exclude stenosis of the anterior cerebral arteries. Peak systolic, minimal diastolic, and mean flow velocities (PSV, MDV, and MFV, cm/s), pulsatility index (PI), and resistance index (RI) were obtained at five points along the M1 portion of the MCA with 5mm intervals insonation depths from the temporal windows [29, 33]. MRIR was designated as the mean ratio of RI along M1 (RI at the shallowest [the most distal] point/ RI at the deepest [the most proximal] point) in each hemisphere [30]. The mean of PI in both MCAs was defined as the average of PIs btained at five insonation points in each hemisphere [25, 30].

Polysomnography

An overnight video polysomnography (Comet digital recording polysomnographic system, Grass Technologies, West Warwick, RI, USA) were performed in every patient, using 6 electroencephalography leads (C3, C4, F3, F4, O1, and O2 in the international 10–20 system), submental electromyography lead, bilateral electrooculography leads [34]. In order to evaluate the respiratory events, nasal thermal sensor, nasal airflow pressure transducer, thoracic and abdominal strain gauges, microphone, position sensor, and finger pulse oximetry were included in the PSG monitoring devices [34].

Sleep stages, arousals, and respiratory events including apnea, hypopnea, and respiratory effort-related arousal (RERA) were scored according to the 2017 version of the American Academy of Sleep Medicine guidelines [34]. Apnea-hypopnea index (AHI) was defined as the mean number of apnea or hypopnea events per hour, respiratory-distress index (RDI) as the mean number of apnea, hypopnea, or RERA events per hour, oxygen desaturation index (ODI) as the mean number of drop in oxygen saturation ≥3% in comparison with immediately preceding basal value, and arousal index as the mean number of arousals per hour [35, 36]. A significant OSA (moderate to severe degree) was defined as an AHI value of ≥15/h [34].

Magnetic resonance imaging analysis

MRI was performed using 1.5-T units (Intera Achieva; Philips Medical Systems, Best, the Netherlands, Signa Excite; GE Medical Systems, Milwaukee, WI, USA, and Verio; Siemens Medical Solutions, Erlangen, Germany) with the protocols including T1/T2-weighted images, fluid-attenuated inversion recovery (FLAIR) sequences, gradient recalled echo/susceptibility weight images (GRE/SWI), and time-of-flight magnetic resonance angiography (MRA). T1/T2-weighted images and FLAIR was obtained with the parameters as follows: slice number = 24–30, slice thickness/gap = 4.0–5.0/0.0–1.0 mm, repetition time/echo time (TR/TE) = 9000–9900/97–163 milliseconds, field-of-view = 220–256 × 220–256 mm, and matrix = 320–352 × 192–256. A neurologist (WJL, with 9 years of experience and blinded to other data) reviews the images to exclude preexisting territorial stroke lesions and the MRA to exclude significant stenosis in the cerebral arteries.

The volumetric analysis of WMH was performed by a neurologist (WJL) blinded to other data, according to the protocols previously described. In brief, FLAIR sequences were registered into an offline workstation. A freeware NeuRoi (Nottingham university, Nottingham, UK) was used to identify the WMH lesion, designate its boundaries, calculate the volume [25, 30, 37]. The periventricular and subcortical WMH volume was separately measured and normalized by the total intracranial volume [30, 38]. The reproducibility of the volumetric analysis was established as good in the previous report [30].

ePVS was designated as small and sharply demarcated ovoid or linear shaped lesions which appeared as hyperintensity in T2 weighted images and hypointensity in T1 weighted images. ePVS was rated in basal ganglia (BG) and centrum semiovale (CS) using the Wardlaw scale of which score range is 0–4 (0 for no, 1 for 1–10, 2 for 11–20, 3 for 21–40, and 4 for >40 ePVS) and total score range is 0–8 [7, 39]. CMB was defined as a 2–10 millimeter punctate hypointensity in GRE/SWI images and lacune was designated as a hyperintense lesion with central hypo-intensity in FLAIR images [7].

Statistical analysis

SPSS 25.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. Pearson coefficients was used to measure correlations between continuous variables, Spearman’s Rho to measure correlations between ordinal variables, paired t test to compare mean values, and chi-square test to compare the frequencies. Age, sex, and variables with P values <0.15 in univariate analyses were included in regression analyses using backward elimination. Linear regression analyses were performed to evaluate the factors associated with WMH volume parameters. WMH volumes were log-transformed to obtain a normal distribution. Multi-collinearity between variables was estimated using the variance inflation factor (VIF). A scatterplot of the standardized predicted values and the standardized residuals was used to check for the linearity of the regression model. Ordinal regression analyses were performed to evaluate the factors associated with ePVS scores. For all analyses, P values < 0.05 were considered as statistically significant.

Results

Ninety-seven patients, including 59 males (60.8%) and 38 females (39.2%), with a mean age of 70.0±10.5 years (range, 50–88 years) were included. The median interval between the evaluations were 82 days (interquartile range, IQR 49–141 days, range -186–236 days) for the PSG and the MRI, 62 days (IQR 28–123 days, range -283–361 days) for the PSG and the TCD, and 17 days (IQR 10–23 days, range -356–72 days) for the MRI and TCD. The indications for the MRI and the TCD analysis were for follow-up evaluation of a pre-existing cerebral WMH in 16 (16.5%) patients or of an old lacunar infarction in 9 (9.3%) patients, and investigations for nonspecific neurologic symptoms such as headache, dizziness, or subjective memory impairment in 72 (74.2%) patients.

In the PSG evaluation, the mean value of total sleep time was 322.6±64.1 min, sleep efficiency was 77.2±14.0%, AHI was 19.1±18.2 /h, RDI was 20.0±18.2 /h, ODI was 20.2±18.3 /h, and arousal index was 25.0±15.0 /h. In the TCD evaluation, the mean MCA MFV was 52.3±16.6 cm/sec, MCA PI was 0.80±0.14, and MRIR was 0.99±0.05. The mean total WMH volume was 0.50±0.41%, subcortical WMH volume was 0.26±0.22%, and periventricular WMH volume was 0.23±0.20% of the total intracranial volume. The median total ePVS score was 4 (2–5), CS ePVS score was 2 (1–3), and BG ePVS score was 1 (1–2). CMB was present in 9 (9.3%) patients and lacunes in 11 (11.3%). Compared to the group with AHI < 15 (N = 48), the group with AHI ≥ 15 (N = 49) showed a higher frequency of male sex, hypertension, hyperlipidemia, higher proportion of N1 sleep stage, lower proportion of N3 sleep stage, higher RDI, ODI, and arousal index in PSG, and higher subcortical WMH volume. However, TCD parameters and the other SVD parameters were comparable between the groups with or without a significant OSA ().

In the univariate analyses for the MCA PI, higher age, shorter total sleep time, lower sleep efficiency, and higher MCA MFV were associated with higher MCA PI, while none of the OSA parameters or other clinical parameters showed a significant association with MCA PI ( and ). Following multivariate linear regression analysis revealed that higher age was the only parameter significantly associated with MCA PI (B coefficient = 0.007; 95% confidence interval [CI] 0.004–0.009; P<0.001, ).

For MRIR, univariate analyses showed that RDI, the proportion of N3 sleep stage, and the presence of atrial fibrillation were associated with MRIR ( and ). In linear regression analysis, higher RDI (B = 0.003; 95% CI 0.001–0.005; P = 0.021) and lower proportion of N3 sleep stage (B = -0.001; 95% CI -0.002–0.000; P = 0.030) were associated with higher MRIR ().

Univariate analyses for the total WMH volume revealed that higher age, shorter total sleep time, higher AHI, RDI, ODI, and arousal index, higher MCA PI, higher MRIR, and the presence of diabetes mellitus or hyperlipidemia were associated with higher WMH volume ( and ). In following multivariate linear regression analysis, age (B = 0.032; 95% CI 0.018–0.046; P<0.001), AHI (B = 0.008; 95% CI 0.001–0.016; P = 0.020), MCA PI (B = 1.001; 95% CI 0.011–1.990; P = 0.047), and MRIR (B = 3.775; 95% CI 1.232–6.318; P = 0.004) were associated with the log-transformed total WMH volume (). For subcortical WMH volume, age (B = 0.026; 95% CI 0.013–0.039; P<0.001), AHI (B = 0.015; 95% CI 0.007–0.022; P<0.001), and MRIR (B = 3.964; 95% CI 1.346–6.583; P = 0.013) were associated with the log-transformed subcortical WMH volume. However, the log-transformed periventricular WMH volume was associated with ODI (B = 0.006; 95% CI 0.001–0.010; P = 0.049), along with age (B = 0.032; 95% CI 0.018–0.046; P<0.001), MCA PI (B = 1.107; 95% CI 0.005–2.210; P = 0.049) and MRIR (B = 3.512; 95% CI 1.220–5.803; P = 0.016) (Tables and and for the univariate analyses). In every analysis, the scatterplot of the standardized predicted values and the standardized residuals showed a random and even distribution of the standardized residuals around the zero line. VIF values for each variable were <1.7.

In univariate analyses for ePVS, total ePVS score was associated with higher age, AHI, RDI, MRIR, and MCA PI, and the presence of diabetes mellitus ( and ). Following multivariate ordinal regression analysis revealed that total ePVS score was associated with age (B = 0.069; 95% CI 0.001–0.016; P = 0.001), AHI (B = 0.024; 95% CI 0.003–0.045; P = 0.026), and MRIR (B = 10.264; 95% CI 3.183–17.346; P = 0.020, ). Similarly, CS ePVS score was associated with age (B = 0.061; 95% CI 0.020–0.103; P = 0.004), AHI (B = 0.026; 95% CI 0.004–0.048; P = 0.019), and MRIR (B = 7.264; 95% CI 2.183–12.345; P = 0.036). However, BG ePVS was associated with age (B = 0.062; 95% CI 0.016–0.108; P = 0.008), MRIR (B = 9.764; 95% CI 2.967–16.373; P = 0.031), and the presence of hypertension (B = 1.602; 95% CI 0.652–2.551; P = 0.001), but only marginally with RDI (B = 0.022; 95% CI -0.001–0.045; P = 0.060, Tables and and for the univariate analyses). None of the clinical, PSG, or TCD parameters was associated with the presence of CMB or lacunes. Multivariate analysis was not performed due to the small numbers of the patients with CMB or lacunes ().

Discussion

The purpose of the current study was to investigate whether the OSA severity was associated with the cerebrovascular compliance and to evaluate the associations of the OSA severity factors with the SVD parameters. This study found that RDI was significantly associated with the TCD marker for cerebral microvascular compliance, MRIR, but not with another marker for cerebrovascular remodeling, MCA PI. AHI and those cerebral vascular remodeling parameters were independently associated with the cerebral WMH volume and ePVS scores. Additionally, AHI was significantly associated with the subcortical SVD parameters such as subcortical WMH volume and CS ePVS score, whereas ODI was associated with WMH volume in deep structures. These findings are concordant to that of a recent meta-analysis, which reported that moderate to severe OSA is positively associated with WMH and silent brain infarction, but not with CMBs [40].

The major finding of the current study is that OSA is associated with cerebral SVD independently from the reduced cerebrovascular compliance. This finding suggests that OSA influences the pathogenesis of SVD by multiple mechanisms and some of them might be distinct from the chronic cerebrovascular remodeling. Considering that chronic aging related cerebrovascular remodeling process has progressive and irreversible feature [2, 41, 42], the finding of this study also indicates that the effect of OSA on the SVD might be reversible in some extent. Previous studies reported that continuous positive airway pressure (CPAP) treatment reversed the altered diffusion tensor image parameters for the white matter integrity and the voxel-based morphometry based gray matter volume parameters in patients with OSA, and explained the reversibility by the improvement of the early osmotic changes in the cells induced by mild ischemia and the inflammation that impairs the cell membrane integrity [27, 28]. Additionally, surgical treatment for OSA by relocation pharyngoplasty, a variant of uvulopalatopharyngoplasty after, also improved the level of high sensitivity C-reactive protein and reduced cardiovascular risk in subjects with OSA [43, 44].

Some plausible pathophysiologic link might explain the association between OSA and SVD independent from the vascular remodeling process. Recent findings that sleep activates the perivascular system function, which is a major pathway for the clearance of cerebral wastes to maintain brain homeostasis of which dysfunction is associated with the pathogenesis of SVD [19, 45, 46]. Sleep induced amplification of the very low frequency oscillations in the cerebral flow velocity might mediate the activation of this system, and disturbed sleep is associated with the impaired regulation of the major cerebral wastes such as β-amyloid or tau proteins [19, 25]. Adequate regulation of the cerebral blood flow pulsation and the CSF recirculation is required for the functioning of the cerebral waste clearance system [37, 47]. Therefore, respiratory event related abrupt intrathoracic pressure increment and the disruption of the sleep structures by frequent arousals might significantly interfere with the cerebral waste clearance during sleep [13, 26]. Additionally, intermittent brain hypoxia provokes oxidative stress and activates inflammatory cascade, which results in the disruption of the BBB integrity and the glial and neuronal cell damage [18, 24]. Respiratory event during sleep also provokes paroxysmal cardiac arrhythmia that is associated with the pathogenesis of SVD [20, 48]. As those pathologic effects can be efficiently prevented by CPAP treatment, OSA might be considered as another modifiable risk factor for the cerebral SVD progression, independent from the conventional vascular risk factors ().

Schematic explanation of the pathophysiologic link between obstructive sleep apnea and cerebral small vessel disease.

The red lines with arrowheads denotes the pathophysiologic mechanisms dependent on the cerebral vascular remodeling process and the blue lines denotes the mechanisms independent from the cerebral vascular remodeling process. SNS: sympathetic nerve system, BBB: blood brain barrier, and SVD: small vessel disease.

Another major finding of the current study is that the effect of AHI on the SVD was different between the brain regions. AHI was significantly associated with the subcortical SVD parameters. However, the SVD parameters of periventricular or basal ganglia was not associated with AHI but rather with ODI, and the conventional cerebrovascular compliance factors such as the presence of hypertension, MCA PI, and MRIR. This might be due to the difference in the dominant pathomechanism of SVD between the subcortical and deep brain structures. As periventricular and basal ganglia have less production of cerebral wastes and are supplied the highly compliant perforating arterioles ramifying directly and perpendicularly from the M1 of MCA, those regions might be less dependent to the sleep-related cerebral waste clearance system function and more susceptible to the conventional cerebrovascular remodeling or the hypoxic damage resulting from the respiratory events during sleep, measured by ODI [7, 35, 37, 38, 47, 49].

Additionally, this study also observed that RDI was associated with higher MRIR, a marker for a reduced compliance of the perforating arterioles ramifying from M1 of MCA [30]. Considering that RDI reflects the burden of sympathetic activation by sleep related respiratory events, and is associated with the development of hypertension and coronary artery disease [50, 51], this association indicates that sympathetic activation during sleep has a major role in the chronic reduction of the cerebral microvascular compliance.

Several limitations in this study need to be addressed. First, due to the retrospective design, the clinical profiles of the study population and the indications for the MRI and the TCD evaluations were heterogeneous. For instance, a history of lacunar infarction or subjective memory impairment might have implicated in the severity of cerebral WMH. Second, the intervals between the PSG, MRI, and TCD were unstandardized. Therefore, the WMH burden at the time of MRI evaluation might be different from that at the time when PSG or the TCD was performed, although the patients were stable with neurological status during the study intervals. Third, due to the relatively small study population, some factors with actual pathophysiologic relevance might have not reached a statistical significance. Fourth, due to the cross-sectional design, the findings of the current study did not ensure the causative relationship among the OSA, vascular remodeling, and the progression of WMH. Future prospective studies with larger study populations, standardized follow-up protocols, and evaluation for the effect of CPAP treatment are warranted to clarify the clinical significance of OSA in the pathomechanism of cerebral WMH and the possible therapeutic effect.

Correlation coefficients among the continuous or ordinal variables.

(DOCX)

Click here for additional data file.

Univariate analyses for categorical parameters associated with white-matter hyperintensity volume.

(DOCX)

Click here for additional data file.

Profiles of clinical, polysomnography, and transcranial cerebrovascular compliance markers in patients with or without cerebral microbleeds or lacunes.

(DOCX)

Click here for additional data file.

STROBE statement—checklist of items that should be included in reports of cross-sectional studies.

(DOCX)

Click here for additional data file.

(XLSX)

Click here for additional data file.

7 Oct 2021

PONE-D-21-27488Effect of obstructive sleep apnea on cerebrovascular compliance and cerebral small vessel diseasePLOS ONE

Dear Dr. Lee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 21 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“This work was supported by a research grant funded by the Korean Society of Neurosonology, Republic of Korea.”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This work was supported by a research grant funded by the Korean Society of Neurosonology, Republic of Korea.”

We note that you have provided additional information within the Acknowledgements Section. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by a research grant funded by the Korean Society of Neurosonology, Republic of Korea”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

7.Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Well written study. Reviewers suggest minor revisions

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Interesting paper, minor corrections to improve the quality:

Introduction

-line 55, Subcortical ischemic vascular dementia (SIVD) is very common among older people, but has no approved treatment. A recent randomized study has shown that remote ischemic conditioning (RIC) reduces the recurrence of ischemic stroke and is an effective therapy for patients with SIVD. please cite doi: 10.1186/s12883-019-1435-y.

- line 60, elderly patients are known to have an increased risk of OSAS, with a prevalence of more severe forms after 65 than younger patients. The same severity of obstructive sleep apnea has also been shown to be related to olfactory disorders in the patient with obstructive sleep apnea, the origin of which could be attributed to disorders of the central nervous system. please cite doi:10.1007/s00405-020-06316-w.

line 70, please cite doi:10.14639/0392-100X-895

Methods and results well structured and clearly expressed

Discussion

line 311, also surgical approaches demonstrated improvement of obstructive sleep apnea syndrome (OSAS) and changes in high sensitivity C-reactive protein (hs-CRP) concentrations have been reported after transfer pharyngoplasty (RP), an elevated variant of uvulopalatopharyngoplasty, reducing cardiovascular risk in subjects with obstructive sleep apnea.

please cite doi:10.1177/0194599810395104 and doi:10.1007/s00405-020-05883-2

Reviewer #2: The paper examined an interesting topic. I support its approval suggesting some minor corrections to improve the quality:

Introduction:

Line 60: Reported incidence of OSA is from 5.6% to 60% in people over 65 (cite doi: 10.3390/ijerph17031120) while SVD presents an increased one from 6% at age 60 to 28% at age 80 (cite doi: 10.3390/ijerph17031120).

Line 70: The endothelial dysfunction, may be related to the consequent generation of reactive oxygen species (ROS) and pro-inflammatory molecules, resulting in microvascular damage in OSA patients (cite doi.org/10.3390/jcm10020277).

Methods: clearly expressed and structured

Results: well written and exhaustive.

Discussion:

Line 295: A recent meta-analysis reported that moderate to severe OSA is positively associated with WMH and SBI but not CMBs or PVS (cite doi: 10.1093/sleep/zsz264).

In all paper put the dots after the brackets.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

13 Oct 2021

Effect of obstructive sleep apnea on cerebrovascular compliance and cerebral small vessel disease

Manuscript No.: PONE-D-21-27488

We are grateful for the thorough review and kind advices that were of great help to improve the quality of our manuscript. The manuscript was revised to clarify the issues raised by the reviewers. The changes and authors’ opinions according to the reviewers’ comments are summarized below. We also enabled the "track changes" feature in the manuscript.

REVIEWER #1:

General Comments:

Interesting paper, minor corrections to improve the quality

Specific Comments:

#1. Introduction

-Line 55, Subcortical ischemic vascular dementia (SIVD) is very common among older people, but has no approved treatment. A recent randomized study has shown that remote ischemic conditioning (RIC) reduces the recurrence of ischemic stroke and is an effective therapy for patients with SIVD. please cite doi: 10.1186/s12883-019-1435-y.

Line 60, elderly patients are known to have an increased risk of OSAS, with a prevalence of more severe forms after 65 than younger patients. The same severity of obstructive sleep apnea has also been shown to be related to olfactory disorders in the patient with obstructive sleep apnea, the origin of which could be attributed to disorders of the central nervous system. please cite doi:10.1007/s00405-020-06316-w.

Line 70, please cite doi:10.14639/0392-100X-895

**Response: We thank the reviewer for this discerning advices and recommendation of important up-to-date articles regarding the pathomechanism of OSA. We revised the relevant sentences in the Introduction and added the articles the reviewer has recommended.

#2. Line 311, also surgical approaches demonstrated improvement of obstructive sleep apnea syndrome (OSAS) and changes in high sensitivity C-reactive protein (hs-CRP) concentrations have been reported after transfer pharyngoplasty (RP), an elevated variant of uvulopalatopharyngoplasty, reducing cardiovascular risk in subjects with obstructive sleep apnea.

please cite doi:10.1177/0194599810395104 and doi:10.1007/s00405-020-05883-2

**Response: We again thank the reviewer for this comment. We revised the Discussion section and added the articles the reviewer has recommended.

REVIEWER #2:

General Comments:

The paper examined an interesting topic. I support its approval suggesting some minor corrections to improve the quality.

Specific Comments:

1. Introduction:

Line 60: Reported incidence of OSA is from 5.6% to 60% in people over 65 (cite doi: 10.3390/ijerph17031120) while SVD presents an increased one from 6% at age 60 to 28% at age 80 (cite doi: 10.3390/ijerph17031120).

Line 70: The endothelial dysfunction, may be related to the consequent generation of reactive oxygen species (ROS) and pro-inflammatory molecules, resulting in microvascular damage in OSA patients (cite doi.org/10.3390/jcm10020277).

**Response: We thank the reviewer for this comments and recommendation of important up-to-date articles regarding the pathomechanism of OSA. We revised the relevant sentences in the Introduction and added the articles the reviewer has recommended.

2. Line 295: A recent meta-analysis reported that moderate to severe OSA is positively associated with WMH and SBI but not CMBs or PVS (cite doi: 10.1093/sleep/zsz264).

**Response: We thank the reviewer for informing us about this article. According to the reviewer’s recommendation, we revised the relevant sentences and added the articles the reviewer has recommended.

3. In all paper put the dots after the brackets.

**Response: We applied the changes the reviewer has requested, throughout the manuscript.

Once again, we thank the editor and the reviewers for the thoughtful comments about our work. We hope that this revision will meet the reviewers' approval.

Sincerely,

Yong-Seok Lee, MD, PhD

Department of Neurology, College of Medicine Seoul National University, Seoul National University-Seoul Metropolitan Government Boramae Medical Center

Dongjak-gu, Shindaebang-dong, Boramae 5 Road 20, 156-707, Seoul, Republic of Korea

Tel: 82-2-870-2476, Fax: 82-2-831-2826, E-mail: mercades@snu.ac.kr

And

Hyun-Woo Nam, MD, PhD

Department of Neurology, College of Medicine Seoul National University, Seoul National University-Seoul Metropolitan Government Boramae Medical Center

Dongjak-gu, Shindaebang-dong, Boramae 5 Road 20, 156-707, Seoul, Republic of Korea

Tel: 82-2-870-2471, Fax: 82-2-831-2826, E-mail: hwnam85@gmail.com

Submitted filename: PONE-D-21-27488-Response to Reviewer Comments.docx

Click here for additional data file.

20 Oct 2021

Effect of obstructive sleep apnea on cerebrovascular compliance and cerebral small vessel disease

PONE-D-21-27488R1

Dear Dr. Lee,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

interesting and well-structured paper, I find it useful to clarify some aspects related to the complications of OSA. the authors improved the text in accordance with the reviewers' suggestions. Well done. Compliments

Reviewers' comments:

-

3 Nov 2021

PONE-D-21-27488R1

Effect of obstructive sleep apnea on cerebrovascular compliance and cerebral small vessel disease

Dear Dr. Lee:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Giannicola Iannella

Academic Editor

PLOS ONE

Table 1

Clinical, laboratory, and white matter hyperintensity profiles of the study population.

	Total (N = 97)	AHI < 15 (N = 48)	AHI ≥ 15 (N = 49)	P
Age (years)	70.0±10.5	69.2±10.4	70.9±10.6	0.250
Male sex (%)	59 (60.8)	19 (39.6)	40 (81.6)	<0.001**
Hypertension (%)	60 (61.9)	24 (50.0)	36 (73.5)	0.017*
Diabetes mellitus (%)	29 (29.9)	11 (22.9)	18 (36.7)	0.140
Hyperlipidemia (%)	29 (29.9)	9 (18.8)	20 (40.8)	0.017*
Heart failure (%)	3 (3.1)	2 (4.2)	1 (2.0)	0.550
Atrial fibrillation (%)	7 (7.2)	3 (6.3)	4 (8.2)	0.719
Polysomnography findings
Time in bed (min)	420.3±44.9	422.9±33.7	417.9±54	0.585
Total sleep time (min)	322.6±64.1	326.3±64.1	318.9±64.6	0.569
Sleep efficiency (%)	77.2±14.0	77.8±13.7	76.6±14.5	0.689
Stage N1 (%)	21.4±13.5	15.1±10.5	27.6±13.4	<0.001**
Stage N2 (%)	53.0±60.4	59.8±74.4	46.6±42.9	0.288
Stage N3 (%)	15.3±9.6	17.4±10.8	13.3±7.8	0.034
Stage REM sleep (%)	18.8±8.5	18.9±7.0	18.6±9.8	0.875
Sleep-onset latency (min)	12.2±12.9	13.8±14.6	10.5±10.9	0.216
REM sleep latency (min)	109.5±72.4	102.8±51.3	116.2±88.4	0.362
Apnea-hypopnea index (/h)	19.1±18.2	4.8±4.2	33.1±15.6	<0.001**
Respiratory distress index (/h)	20.0±18.2	6.0±5.3	33.7±15.7	<0.001**
Oxygen-desaturation index (/h)	20.2±18.3	5.1±4.2	34.5±15.7	<0.001**
Arousal index (/h)	25.0±15.0	17.0±9.0	32.9±15.6	<0.001**
Transcranial Doppler and MRI findings
MCA MFV (cm/sec)	52.3±16.6	50.8±11.0	53.8±20.7	0.372
MCA PI	0.80±0.14	0.78±0.13	0.82±0.15	0.163
MRIR	0.99±0.05	0.99±0.05	0.99±0.05	0.336
WMH total volume (%)	0.50±0.41	0.44±0.34	0.56±0.47	0.137
WMH subcortical volume (%)	0.26±0.22	0.22±0.17	0.31±0.25	0.045*
WMH periventricular volume (%)	0.23±0.20	0.22±0.17	0.25±0.22	0.363
Total ePVS score	4 (2–5)	4 (2–4)	4 (2.5–5)	0.107
CS ePVS score	2 (1–3)	2 (1–3)	2 (2–3)	0.113
BG ePVS score	1 (1–2)	1 (1–2)	1 (1–2)	0.225
Presence of CMB	9 (9.3)	5 (10.4)	4 (8.2)	0.706
Presence of Lacunes	11 (11.3)	5 (10.4)	6 (12.2)	0.779

Data are reported as number (percentage), as mean± standard deviation, or as median (interquartile range, IQR). AHI: apnea-hypopnea index, REM: rapid eye movement, MCA: middle cerebral artery, MFV: mean flow velocity, PI: pulsatility index, MRIR: mean middle cerebral artery resistance index ratio, WMH: white matter hyperintensity, ePVS: enlarged perivascular space, CS: centrum semiovale, BG: basal ganglia, and CMB: cerebral microbleeds.

*P<0.05 and

**P<0.01.

Table 2

Linear regression analyses for factors associated with the cerebrovascular compliance markers.

MCA PI a	B (95% CI)	β	P
	0.343 (0.169–0.516)		<0.001**
Age (year)	0.007 (0.004–0.009)	0.480	<0.001**
MRIR b	B (95% CI)	β	P
	1.002 (0.984–1.020)		<0.001**
Stage N3 (%)	-0.001 (-0.002–0.000)	-0.210	0.030*
Respiratory distress index (/h)	0.003 (0.001–0.005)	0.226	0.021*

aR2 = 0.230 and P<0.001 and

bR2 = 0.247 and P<0.001 for the linear regression equation.

B: unstandardized coefficient, β: standardized coefficient, CI: confidence interval, MCA: middle cerebral artery, PI: pulsatility index, and MRIR: mean middle cerebral artery resistance index ratio.

*P<0.05 and

**P<0.01.

Table 3

Linear regression analyses for factors associated with the log-transformed value of the white-matter hyperintensity volumes.

WMH total volume (%, log-transformed)a	B (95% CI)	β	P
Intercept	-8.135 (-10.815–-5.456)		<0.001**
Age (year)	0.032 (0.018–0.046)	0.415	<0.001**
Apnea-hypopnea index (/h)	0.008 (0.001–0.016)	0.191	0.020*
MCA PI	1.001 (0.011–1.990)	0.180	0.047*
MRIR	3.775 (1.232–6.318)	0.234	0.004**
WMH subcortical volume (%, log-transformed)b	B (95% CI)	β	P
Intercept	-7.977 (-10.528–-5.427)	0.000	<0.001**
Age (year)	0.026 (0.013–0.039)	0.356	<0.001**
Apnea-hypopnea index (/h)	0.015 (0.007–0.022)	0.336	<0.001**
MCA PI	1.002 (-0.017–2.021)	0.178	0.054
MRIR	3.964 (1.346–6.583)	0.243	0.013*
WMH periventricular volume (%, log-transformed)c	B (95% CI)	β	P
Intercept	-9.217 (-12.04–-6.394)	0.000	<0.001**
Age (year)	0.032 (0.018–0.046)	0.418	<0.001**
Oxygen desaturation index (/h)	0.006 (0.001–0.010)	0.192	0.046*
MCA PI	1.107 (0.005–2.210)	0.188	0.049*
MRIR	3.512 (1.220–5.803)	0.224	0.016**

aR2 = 0.424 and P<0.001,

bR2 = 0.676 and P<0.001, and

cR2 = 0.619 and P<0.001 for the linear regression equation.

B: unstandardized coefficient, β: standardized coefficient, CI: confidence interval, WMH: white matter hyperintensity, MCA: middle cerebral artery, PI: pulsatility index, and MRIR: mean middle cerebral artery resistance index ratio.

*P<0.05 and

**P<0.01.

Table 4

Linear regression analyses for factors associated with the enlarged perivascular space scores.

Total ePVS score	B (95% CI)	P
Age (year)	0.069 (0.029–0.108)	0.001**
Apnea-hypopnea index (/h)	0.024 (0.003–0.045)	0.026*
MCA PI	2.556 (-0.441–5.554)	0.095
MRIR	10.264 (3.183–17.346)	0.020*
Thresholds	B (SE)
0	18.388 (4.206)
1	19.487 (4.227)
2	20.846 (4.282)
3	21.631 (4.317)
4	23.128 (4.383)
5	25.197 (4.481)
CS ePVS score	B (95% CI)	P
Age (year)	0.061 (0.020–0.103)	0.004**
Apnea-hypopnea index (/h)	0.026 (0.004–0.048)	0.019*
MCA PI	2.753 (-0.363–5.868)	0.083
MRIR	7.264 (2.183–12.345)	0.036*
Thresholds	B (SE)
0	13.385 (4.324)
1	14.946 (4.367)
2	16.833 (4.434)
3	19.793 (4.554)
BG ePVS score	B (95% CI)	P
Age (year)	0.062 (0.016–0.108)	0.008**
Respiratory distress index (/h)	0.022 (-0.001–0.045)	0.060
MCA PI	2.137 (-1.183–5.458)	0.207
MRIR	9.764 (2.967–16.373)	0.031*
Hypertension	1.602 (0.652–2.551)	0.001**
Thresholds	B (SE)
0	19.491 (4.88)
1	23.079 (5.082)
2	26.434 (5.263)

aR2 = 0.388 and P<0.001, bR2 = 0.384 and P = 0.001, and cR2 = 0.378 and P<0.001 for the regression equation.

B: unstandardized coefficient, CI: confidence interval, ePVS: enlarged perivascular space, CS: centrum semiovale, BG: basal ganglia, MCA: middle cerebral artery, PI: pulsatility index, and MRIR: mean middle cerebral artery resistance index ratio.

*P<0.05 and

**P<0.01.